John L Sievenpiper1, Russell J de Souza, Adrian I Cozma, Laura Chiavaroli, Vanessa Ha, Arash Mirrahimi. 1. aToronto 3D Knowledge Synthesis and Clinical Trials Unit, Clinical Nutrition and Risk Factor Modification Centre, St. Michael's Hospital, Toronto bDepartment of Pathology and Molecular Medicine, Faculty of Health Sciences, McMaster University cDepartment of Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, McMaster University, Hamilton dDepartment of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto eSchool of Medicine, Faculty of Health Sciences, Queen's University, Kingston, Ontario, Canada.
Abstract
PURPOSE OF REVIEW: Fructose is seen as uniquely contributing to the pandemics of obesity and its cardiometabolic complications. Much of the evidence for this view derives from the unique biochemical, metabolic, and endocrine responses that differentiate fructose from glucose. To understand whether these proposed mechanisms result in clinically meaningful modification of cardiovascular risk in humans, we update a series of systematic reviews and meta-analyses of controlled feeding trials to assess the cardiometabolic effects of fructose in isocaloric replacement for glucose. RECENT FINDINGS: A total of 20 controlled feeding trials (n = 344) have investigated the effect of fructose in/on cardiometabolic endpoints. Pooled analyses show that although fructose may increase total cholesterol, uric acid, and postprandial triglycerides in isocaloric replacement for glucose, it does not appear to be any worse than glucose in its effects on other aspects of the lipid profile, insulin, or markers of nonalcoholic fatty liver disease. It may also have important advantages over glucose for body weight, glycemic control, and blood pressure. SUMMARY: Depending on the cardiometabolic endpoint in question, fructose has variable effects when replacing glucose. In the absence of clear evidence of net harm, there is no justification to replace fructose with glucose in the diet.
PURPOSE OF REVIEW: Fructose is seen as uniquely contributing to the pandemics of obesity and its cardiometabolic complications. Much of the evidence for this view derives from the unique biochemical, metabolic, and endocrine responses that differentiate fructose from glucose. To understand whether these proposed mechanisms result in clinically meaningful modification of cardiovascular risk in humans, we update a series of systematic reviews and meta-analyses of controlled feeding trials to assess the cardiometabolic effects of fructose in isocaloric replacement for glucose. RECENT FINDINGS: A total of 20 controlled feeding trials (n = 344) have investigated the effect of fructose in/on cardiometabolic endpoints. Pooled analyses show that although fructose may increase total cholesterol, uric acid, and postprandial triglycerides in isocaloric replacement for glucose, it does not appear to be any worse than glucose in its effects on other aspects of the lipid profile, insulin, or markers of nonalcoholic fatty liver disease. It may also have important advantages over glucose for body weight, glycemic control, and blood pressure. SUMMARY: Depending on the cardiometabolic endpoint in question, fructose has variable effects when replacing glucose. In the absence of clear evidence of net harm, there is no justification to replace fructose with glucose in the diet.
Authors: Elisabeth T M Leermakers; Janine F Felix; Vincent W V Jaddoe; Hein Raat; Oscar H Franco; Jessica C Kiefte-de Jong Journal: Int J Behav Nutr Phys Act Date: 2015-09-17 Impact factor: 6.457
Authors: Lianne M S Bouwman; José M S Fernández-Calleja; Hans J M Swarts; Inge van der Stelt; Annemarie Oosting; Jaap Keijer; Evert M van Schothorst Journal: Mol Nutr Food Res Date: 2017-12-11 Impact factor: 5.914
Authors: Miguel Baena; Gemma Sangüesa; Alberto Dávalos; María-Jesús Latasa; Aleix Sala-Vila; Rosa María Sánchez; Núria Roglans; Juan Carlos Laguna; Marta Alegret Journal: Sci Rep Date: 2016-05-19 Impact factor: 4.379